Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
06 Agosto 2024 - 7:00AM
Business Wire
As required by the rules of the Nasdaq Stock Market, Twist
Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a
company enabling customers to succeed through its offering of
high-quality synthetic DNA using its silicon platform, today
announced that it has granted a total of 94,200 restricted stock
units (“RSUs”) to 30 recently hired individuals as an inducement
material to their acceptance of employment with Twist. The
employment inducement awards were granted under Twist’s Inducement
Equity Incentive Plan and related form of restricted stock award
agreement in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement plan is used exclusively for the grant of equity
awards to individuals who were not previously employees of Twist,
or following a bona fide period of non-employment, as an inducement
material to such individuals entering into employment with Twist,
pursuant to Nasdaq Listing Rule 5635(c)(4).
The RSUs vest over a 48-month period for each employee as
follows: 25% vests on the one year anniversary of the start date of
the employee (the “Vesting Commencement Date”), and 1/16 of the
RSUs vest on each quarterly anniversary (or the last day of the
month if no such day exists) of the Vesting Commencement Date
thereafter, subject to the employee’s continued service through
each vesting date.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240806706655/en/
For Investors: Angela Bitting SVP, Corporate Affairs
925-202-6211 abitting@twistbioscience.com
For Media: Amanda Houlihan Communications Manager
774-265-5334 ahoulihan@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Twist Bioscience (NASDAQ:TWST)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024